Aby J. Mathew Sells 404 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 404 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $10,916.08. Following the sale, the executive vice president now owns 262,715 shares in the company, valued at approximately $7,098,559.30. This trade represents a 0.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

BioLife Solutions Stock Down 3.9 %

BioLife Solutions stock opened at $26.61 on Friday. BioLife Solutions, Inc. has a 52 week low of $14.50 and a 52 week high of $28.88. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -25.10 and a beta of 1.92. The company’s 50-day moving average price is $25.99 and its two-hundred day moving average price is $24.29. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Fred Alger Management LLC boosted its stake in BioLife Solutions by 6.0% during the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock valued at $33,841,000 after purchasing an additional 88,840 shares in the last quarter. State Street Corp boosted its stake in BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares in the last quarter. Geode Capital Management LLC raised its position in BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after acquiring an additional 18,473 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in BioLife Solutions by 9.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock valued at $17,034,000 after acquiring an additional 66,422 shares during the last quarter. Finally, Rockefeller Capital Management L.P. lifted its holdings in BioLife Solutions by 81.3% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after acquiring an additional 262,504 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Benchmark reiterated a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. HC Wainwright cut their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. TD Cowen upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Northland Securities lifted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Craig Hallum boosted their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, BioLife Solutions presently has an average rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.